# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-110979
Filing Date
2025-11-14
Accepted
2025-11-14 16:50:40
Documents
66
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | QUARTERLY REPORT | ea0262047-10q_actinium.htm iXBRL | 10-Q | 946811
2 | CERTIFICATION | ea026204701ex31-1_actinium.htm | EX-31.1 | 10006
3 | CERTIFICATION | ea026204701ex31-2_actinium.htm | EX-31.2 | 9863
4 | CERTIFICATION | ea026204701ex32-1_actinium.htm | EX-32.1 | 3922
5 | CERTIFICATION | ea026204701ex32-2_actinium.htm | EX-32.2 | 3875
6 | LETTER FROM NOVARTIS PHARMACEUTICALS CORPORATION, DATED AUGUST 5, 2025 | ea026204701ex99-1_actinium.htm | EX-99.1 | 32562
7 | GRAPHIC | image_001.jpg | GRAPHIC | 34031
8 | GRAPHIC | image_002.jpg | GRAPHIC | 102133
9 | GRAPHIC | image_003.jpg | GRAPHIC | 29571
10 | GRAPHIC | image_004.jpg | GRAPHIC | 14394
11 | GRAPHIC | image_005.jpg | GRAPHIC | 12234
12 | GRAPHIC | image_006.jpg | GRAPHIC | 18081
13 | GRAPHIC | image_007.jpg | GRAPHIC | 15905
14 | GRAPHIC | image_008.jpg | GRAPHIC | 14501
15 | GRAPHIC | image_009.jpg | GRAPHIC | 14657
16 | GRAPHIC | image_010.jpg | GRAPHIC | 12931
17 | GRAPHIC | image_011.jpg | GRAPHIC | 21373
18 | GRAPHIC | image_012.jpg | GRAPHIC | 10974
19 | GRAPHIC | image_013.jpg | GRAPHIC | 16762
20 | GRAPHIC | image_014.jpg | GRAPHIC | 11424
21 | GRAPHIC | image_015.jpg | GRAPHIC | 10442
22 | GRAPHIC | image_016.jpg | GRAPHIC | 11389
23 | GRAPHIC | image_017.jpg | GRAPHIC | 10043
24 | GRAPHIC | ex99-1_001.jpg | GRAPHIC | 7815
| Complete submission text file | 0001213900-25-110979.txt |  | 4880589

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
25 | XBRL SCHEMA FILE | atnm-20250930.xsd | EX-101.SCH | 26106
26 | XBRL CALCULATION FILE | atnm-20250930_cal.xml | EX-101.CAL | 25604
27 | XBRL DEFINITION FILE | atnm-20250930_def.xml | EX-101.DEF | 139283
28 | XBRL LABEL FILE | atnm-20250930_lab.xml | EX-101.LAB | 303148
29 | XBRL PRESENTATION FILE | atnm-20250930_pre.xml | EX-101.PRE | 156665
68 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0262047-10q_actinium_htm.xml | XML | 329624

Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 251487725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)